Lantheus Medical Imaging, Inc.

Arqule, Inc.

Wyeth

Tokai Pharmaceuticals, Inc.

Other

Bristol-myers Squibb Pharma Company

David S. Casebier

Michael T. Azure

Heike S. Radeke

Douglas D. Dischino

Acp Lantern Acquisition, Inc.

David S Casebier

Simon P Robinson

Heike S Radeke

Thomas David Harris

Ajay Purohit

Michael T Azure

Edward H Cheesman

Richard R Cesati

Joseph C Hogan, Jr

Derek Cecil Cole

Ming Yu

Kevin R Woller

Richard J Looby

William Jay Moore

Joseph Raymond Stock

Douglas Dischino

Kristina Martha Kutterer

Anthony Frank Kreft

Robert Anthony Zambias

David A Bolten

Paul Furth

Cheng Tu

Padmaja Yalamanchili

Dennis Michael Kubrak

George Diamantidis

Joel Lazewatsky

Cy Aaron Stein

Charles William Mann

Dennis Martin Kubrak

Jodie Pope Morrison

Mikhail Kagan

Alan Kaplan

Steve Gallion

Thomas D Harris

Douglas D Dischino

Anthony F Kreft, Iii

David C Onthank

Carol Hui Hu

Jaime E Arenas

Lynn Resnick

Matthias Broekema

Paul S Purth

Paul S Furth

Douglas D Dischimo

A method of imaging, the method comprising administering, to a subject, a compound of Structure Alpha, of the formula:

Ligands for imaging cardiac innervation

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release thereby reducing side effects, improved quantitative data, and/or high affinity for VMAT over prior radiotracers. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Contrast agents for myocardial perfusion imaging

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the subject using diagnostic imaging.

Contrast agents for applications including perfusion imaging

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

N-alkoxyamide conjugates as imaging agents

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

Prodrugs of C-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (AR), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia. The disclosure describes methods of synthesizing and using the prodrugs in cancer therapy.

Prodrugs of steroidal CYP17 inhibitors/antiandrogens

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer.

Treatment of prostate cancer

Growing community of inventors

Carlisle, MA, United States of America

David S Casebier